Investigational Drug Information for NNZ-2591
✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug NNZ-2591?
NNZ-2591 is an investigational drug.
There have been 13 clinical trials for NNZ-2591. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2014.
The most common disease conditions in clinical trials are Syndrome, Brain Injuries, Traumatic, and Brain Injuries. The leading clinical trial sponsors are Neuren Pharmaceuticals Limited, Baylor College of Medicine, and International Rett Syndrome Foundation.
Summary for NNZ-2591
|US Patent Applications||11|
|WIPO Patent Applications||7|
|Japanese Patent Applications||0|
|Clinical Trial Progress||Phase 2 (2014-01-01)|
Recent Clinical Trials for NNZ-2591
|An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)||Neuren Pharmaceuticals Limited||Phase 2|
|An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome||Neuren Pharmaceuticals Limited||Phase 2|
|An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)||Neuren Pharmaceuticals Limited||Phase 2|
Clinical Trial Summary for NNZ-2591
Top disease conditions for NNZ-2591
Top clinical trial sponsors for NNZ-2591
US Patents for NNZ-2591
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|